News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Aradigm Corporation Completes Enrollment in Phase 2 Study of Inhaled Liposomal Ciprofloxacin for Bronchiectasis
October 14, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTCBB:ARDM) (“Aradigm”) today announced it completed enrollment in its Phase 2 clinical trial of its inhaled liposomal ciprofloxacin in adult patients with non-cystic fibrosis bronchiectasis.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
MORE ON THIS TOPIC
Breast cancer
Gilead’s Trodelvy, With Keytruda, Slows Disease Progression in Triple-Negative Breast Cancer
April 22, 2025
·
2 min read
·
Tristan Manalac
Breast cancer
AstraZeneca, Daiichi Sankyo Push Enhertu to Frontline Breast Cancer With Phase III Data
April 22, 2025
·
2 min read
·
Tristan Manalac
FDA
FDA’s User Fee Negotiation Teams Gutted by Layoffs: Reuters
April 18, 2025
·
2 min read
·
Tristan Manalac
Tariffs
Biotech’s Next Phase Will Be All-American: Pitchbook
April 17, 2025
·
2 min read
·
Annalee Armstrong